Arlington, TEXAS5 Active Studies

Interstitial Cystitis Clinical Trials in Arlington, TEXAS

Find 5 actively recruiting interstitial cystitis clinical trials in Arlington, TEXAS. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
886
Enrolling

Recruiting Interstitial Cystitis Studies in Arlington

RecruitingArlington, TEXASNCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...

336 participants
Vivace Therapeutics, Inc
View Study Details
RecruitingArlington, TEXASNCT06881251

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis....

240 participants
Janssen Research & Development, LLC
View Study Details
RecruitingArlington, TEXASNCT06038578

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with ...

146 participants
Toray Industries, Inc
View Study Details
RecruitingArlington, TEXASNCT06687967

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male ...

136 participants
Sanofi
View Study Details
RecruitingArlington, TEXASNCT03471117

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing th...

28 participants
The University of Texas at Arlington
View Study Details

About Interstitial Cystitis Clinical Trials in Arlington

Interstitial cystitis/bladder pain syndrome is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It primarily affects women and can significantly impact quality of life. Treatment includes dietary changes, bladder instillations, oral medications, and neuromodulation.

There are currently 5 interstitial cystitis clinical trials recruiting participants in Arlington, TEXAS. These studies are seeking a combined 886 participants. Research is being sponsored by Vivace Therapeutics, Inc, Janssen Research & Development, LLC, Toray Industries, Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Interstitial Cystitis Clinical Trials in Arlington — FAQ

Are there interstitial cystitis clinical trials in Arlington?

Yes, there are 5 interstitial cystitis clinical trials currently recruiting in Arlington, TEXAS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Arlington?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Arlington research site will contact you about next steps.

Are clinical trials in Arlington free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Arlington studies also compensate for your time and travel.

What interstitial cystitis treatments are being tested?

The 5 active trials in Arlington are testing new therapies including novel drugs, biologics, and treatment approaches for interstitial cystitis.

Data updated March 2, 2026 from ClinicalTrials.gov